There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after ...

Doctors can combine immunotherapy with other treatments across various stages of renal cell carcinoma (RCC ... approved a new version of nivolumab (Opdivo Qvantig) for use as a subcutaneous ...

Based on these results, subcutaneous nivolumab was approved for use in renal cell carcinoma, as well as: Subcutaneous injections offer various potential benefits over intravenous infusions.

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer It was not until 2018 when ipilimumab and nivolumab were ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy ... who were ...